Predict your next investment

Venture Capital
merlinbiomed.com

See what CB Insights has to offer

Investments

43

Portfolio Exits

24

About Merlin Biomed Group

Merlin BioMed Group is a Registered Investment Advisor which invests globally in public healthcare companies. Founded in January, 1998, by Dr. Stuart T. Weisbrod, Merlin BioMed Group and its affiliates encompass several hedge funds.Currently, the Merlin BioMed Group investment team consists of 5 investment professionals, including 2 MDs and 1 Ph.D. All draw on their varied healthcare backgrounds and experience to provide our firm with deep and broad industry knowledge spanning later stage biotechnology, pharmaceuticals, medical devices and healthcare services.Our investor base consists of institutions, pension funds, endowments, funds of funds, family offices and high net worth individuals.

Merlin Biomed Group Headquarter Location

424 West 33rd street Ste 520

New York, New York, 10001,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Merlin Biomed Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Merlin Biomed Group in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Merlin Biomed Group Investments

43 Investments

Merlin Biomed Group has made 43 investments. Their latest investment was in Gemin X as part of their Series C on June 6, 2008.

CBI Logo

Merlin Biomed Group Investments Activity

investments chart

Merlin Biomed Group Portfolio Exits

24 Portfolio Exits

Merlin Biomed Group has 24 portfolio exits. Their latest portfolio exit was Cepheid on November 05, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/5/2016

Acq - P2P

$99M

2

1/11/2015

Acq - P2P

$99M

1

12/8/2014

Acquired

$99M

1

11/14/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/28/2014

IPO

Subscribe to see more

Subscribe to see more

10

Date

11/5/2016

1/11/2015

12/8/2014

11/14/2014

7/28/2014

Exit

Acq - P2P

Acq - P2P

Acquired

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.